Download PDF
Int J Sports Med 2012; 33(04): 305-309
DOI: 10.1055/s-0031-1291322
Training & Testing
© Georg Thieme Verlag KG Stuttgart · New York

No Effect of Intravenous Actovegin® on Peak Aerobic Capacity

P. Lee
1   Cardiff University, Institute of Medical Engineering and Medical Physics, Cardiff, United Kingdom
,
L. Nokes
2   Cardiff University, Engineering, Cardiff, United Kingdom
,
P. M. Smith
3   University of Wales Institute, Cardiff School of Sport, Cardiff, United Kingdom
› Author Affiliations
Further Information

Publication History



accepted after revision 03 October 2011

Publication Date:
08 February 2012 (online)

Also available at
    Permissions and Reprints

Abstract

There is much speculation that Actovegin® is ergogenic, but no scientific work has been published in this field. 8 participants [mean(± SD) age, height and mass of 24 (7) years, 1.76 (0.07) m and 80.1 (9.1) kg, respectively] completed 3 exhaustive arm crank ergometry tests. Following Baseline testing 2 further tests were performed 2 h following the injection of either 40 ml of Actovegin® or a saline Placebo. Peak power (Wpeak), peak physiological responses, concentrations of blood glucose and lactate, exercise efficiency (%), VO2 gain (ml·W-1), and the respiratory compensation point (RCP) were determined. Repeated measures ANOVA tests were used to analyse data with significance accepted at p≤0.05. Values of mean (±90% CI) bias were calculated to further explore quantitative differences between trials. Strong trends for variations in Wpeak (p=0.054) and RCP (p=0.054) were evident; likely meaningful effects existed between the Baseline and both injection trials, but only a trivial effect was noted between Placebo and Actovegin® (bias: Wpeak 0.8±3.2 and RCP; 2.5±4.7 W). Concentrations of blood lactate and glucose changed across time, but did not differ between the 3 trials. Our data suggests the Actovegin® is not ergogenic and did not influence functional capacity in the context of the exhaustive, upper-body test employed.

Key words

drug injection - ergogenic aid - doping - arm crank ergometry - haemodialysate
 

  • References

  • 1 Appiah AK. Treatment of severe primary postpartum hemorrhage with a deproteinized hemodialysate. Int J Gynaecol Obste 2002; 7: 75-76
    PubMedSearch in Google Scholar
  • 2 Batterham AM, Hopkins WG. Making meaningful inferences about magnitudes. Int J Sports Physiol Perform 2006; 1: 50-57
    PubMedSearch in Google Scholar
  • 3 Biland L, Hurlimann F, Goor W, Korner WF, Kundig A, Madar G, Widmer LK, Ziegler WJ. Treatment of venous ulcers. A multi-center randomized double-blind study. Vasa 1985; 14: 383-389
    PubMedSearch in Google Scholar
  • 4 Boyarinov GA, Mukhina IV, Penknovich AA, Snopova LB, Zimin YV, Balandina MV, Radaev AM, Skvortsova IE, Prodanets NN. Effects of actovegin on the central nervous system during postischemic period. Bull Exp Biol Med 1998; 126: 993-996
    CrossrefPubMedSearch in Google Scholar
  • 5 Capodaglio P, Bazzini G. Predicting endurance limits in arm cranking exercise with a subjectively based method. Ergonomics 1996; 39: 924-932
    CrossrefPubMedSearch in Google Scholar
  • 6 Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edition Lawrence Erlbaum Associates; 1988
    Search in Google Scholar
  • 7 De rev’yannykh EA, Bel’skaya GN, Knoll EA, Krylova LG, Popov DV. Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke. Neurosci Behav Physiol 2008; 38: 873-875
    CrossrefPubMedSearch in Google Scholar
  • 8 Franklyn-Miller A, Etherington J, McCrory P. Sports and exercise medicine – specialists or snake oil salesmen?. Br J Sports Med 2011; 45: 83-84
    CrossrefPubMedSearch in Google Scholar
  • 9 Harriss DJ, Atkinson G. Update – Ethical Standards in Sport and Exercise Science Research. Int J Sports Med 2011; 32: 819-821
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Hoyer S, Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (Actovegin®). Arch Gerontol Geriatr 1989; 9: 181-192
    CrossrefPubMedSearch in Google Scholar
  • 11 Jacobs PL, Mahoney ET, Johnson B. Reliability of arm Wingate Anaerobic Testing in persons with complete paraplegia. J Spinal Cord Med 2003; 26: 141-144
    PubMedSearch in Google Scholar
  • 12 Kanowski S, Kinzler E, Lehmann E, Schweizer A, Kuntz G. Confirmed clinical efficacy of Actovegin® in elderly patients with organic brain syndrome. Pharmacopsychiatry 1995; 28: 125-133
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Lee P, Rattenberry A, Connelly S, Nokes L. Our experience on Actovegin, is it cutting edge?. Int J Sports Med 2011; 32: 237-241
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Nycomed. http://www.nycomed.com/products/further-therapies/actovegin/ Accessed 10th July, 2011
    PubMed
  • 15 Orchard JW, Best TM, Mueller-Wohlfahrt HW, Hunter G, Hamilton BH, Webborn N, Jaques R, Kenneally D, Budgett R, Phillips N, Becker C, Glasgow P. The early management of muscle strains in the elite athlete: Best practice in a world with a limited evidence basis. Br J Sports Med 2008; 42: 158-159
    CrossrefPubMedSearch in Google Scholar
  • 16 Peronnet F, Massicotte D. Table of nonprotein respiratory quotient: an update. Can J Sport Sci 1991; 16: 23-29
    PubMedSearch in Google Scholar
  • 17 Price MJ, Bottoms L, Smith PM, Nicholettos A. The effects of an increasing versus constant crank rate on peak physiological responses during incremental arm crank ergometry. J Sports Sci 2011; 29: 263-269
    CrossrefPubMedSearch in Google Scholar
  • 18 Price MJ, Collins L, Smith PM, Goss-Sampson M. The effects of cadence and power output upon physiological and biomechanical responses to incremental arm-crank ergometry. Appl Physiol Nutr Metab 2007; 32: 686-692
    CrossrefPubMedSearch in Google Scholar
  • 19 Schoenwald D, Sixt B, Machicao F, Marx E, Haedenkamp G, Bertsch S. Enhanced proliferation of coronary endothelial cells in response to growth factors is synergized by hemodialysate compounds in-vitro. Res Exp Med 1991; 191: 259-272
    CrossrefPubMedSearch in Google Scholar
  • 20 Smith PM, Doherty M, Drake D, Price MJ. The influence of step and ramp type protocols on the attainment of peak physiological responses during arm crank ergometry. Int J Sports Med 2004; 25: 616-621
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Smith PM, Doherty M, Price MJ. The effect of crank rate on physiological responses and exercise efficiency using a range of submaximal workloads during arm crank ergometry. Int J Sports Med 2006; 27: 199-204
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Smith PM, Doherty M, Price MJ. The effect of crank rate strategy on peak aerobic power and peak physiological responses during arm crank ergometry. J Sports Sci 2007; 25: 711-718
    CrossrefPubMedSearch in Google Scholar
  • 23 Smith PM, Price MJ, Doherty M. The influence of crank rate on peak oxygen consumption during arm crank ergometry. J Sports Sci 2001; 19: 955-960
    CrossrefPubMedSearch in Google Scholar
  • 24 Tsitsimpikou C, Tsiokanos A, Tsarouhas K, Schamasch P, Fitch KD, Valasiadis D, Jamurtas A. Medication use by athletes at the Athens 2004 Summer Olympic Games. Clin J Sport Med 2009; 19: 33-38
    CrossrefPubMedSearch in Google Scholar
  • 25 WADA. World Anit-Doping Agency Prohibited List. http://www.wada-ama.org/en/prohibitedlist.ch2 Accessed 21st April, 2011
    PubMed
  • 26 Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32: 1479-1484
    CrossrefPubMedSearch in Google Scholar